Shots:
- Sitryx Therapeutics has granted BI an exclusive license to a preclinical, small molecule program, offering a disease-modifying treatment approach across multiple autoimmune & inflammatory disease indications
- As per the deal, BI will receive an exclusive global license to the multiple assets & related IP to the small molecule inhibitor program, plus it will assume full responsibility for the program, incl. further research, clinical development & commercialization
- On the other hand, Sitryx will receive upfront & near-term payments, along with development, regulatory & commercialization milestone payments totaling >$500M, as well as tiered royalties
Ref: Sitryx | Image: Sitryx & BI | Press Release
Related News: Frontier Biotechnologies and GSK Forge ~$1B Global Licensing Deal for siRNA Therapeutics
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
